CARDIOEMBOLIC STROKE IN LATVIA: PREVENTION AND LONG-TERM OUTCOME

Elina Pucite (), Kristaps Jurjāns (), Evija Miglāne (), Baiba Luriņa (), Oskars Kalējs (), Andrejs Millers () and Zanda Priede ()
Additional contact information
Elina Pucite: Pauls Stradins Clinical University Hospital
Kristaps Jurjāns: Pauls Stradins Clinical University Hospital
Evija Miglāne: Pauls Stradins Clinical University Hospital
Baiba Luriņa: Pauls Stradins Clinical University Hospital
Oskars Kalējs: Pauls Stradins Clinical University Hospital
Andrejs Millers: Pauls Stradins Clinical University Hospital
Zanda Priede: Pauls Stradins Clinical University Hospital

CBU International Conference Proceedings, 2016, vol. 4, issue 0, 615-621

Abstract: INTRODUCTION: Untreated non-valvular atrial fibrillation is one of major causes of stroke. The goal of the study was to evaluate the use of antithrombotic medication stroke prevention and assess long-term stroke outcome.METHODS: This study involved 531 cardio embolic stroke patients of the Paul’s Stradins Clinical University Hospital, Riga, Latvia, in 2014. After discharge the patients or their relatives were interviewed by phone after 30, 90, 180, and 365 days. Standardized questions were asked about the patients’ abilities and use of prescribed secondary prevention medication. The results were compared between patient groups, assigned according to prescribed medications.RESULTS: Of all the patients included in the study, 8.9% were using oral anticoagulants before stroke onset. One year after discharge, 1.44% of patients were not using any preventive medication, 23.56% were using antiplatelet agents, 43.27% warfarin, and 31.73% target-specific oral anticoagulants. The one-year mortality rate was 40.7%. The mortality rate was significantly higher in the patient group using no secondary preventive medication or antiplatelet agents compared to the patient group that used oral anticoagulants.CONCLUSION: Cardio embolic stroke primary and secondary prevention in Latvia is lacking. The study outcomes suggest that action is needed to increase the use of oral anticoagulants in primary stroke prevention in patients with atrial fibrillation. Poor function outcomes, dementia, and patients’ incompliance limits the use of oral anticoagulants in secondary prevention.

Keywords: Atrial fibrillationcardio embolic stroke; stroke mortality; primary stroke prevention; secondary stroke prevention (search for similar items in EconPapers)
Date: 2016
References: Add references at CitEc
Citations:

Downloads: (external link)
https://ojs.journals.cz/index.php/CBUIC/article/view/821/912 (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:aad:iseicj:v:4:y:2016:i:0:p:615-621

DOI: 10.12955/cbup.v4.821

Access Statistics for this article

More articles in CBU International Conference Proceedings from ISE Research Institute
Bibliographic data for series maintained by Petr Hájek ().